The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Regional Cancer Care Associates
Stock and Other Ownership Interests - Regional Cancer Care Associates
A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
David William Pook
Honoraria - Astellas Pharma; Ipsen; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Daniel M. Geynisman
Consulting or Advisory Role - 2nd.MD; AstraZeneca; Eisai; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
 
Filippo G. De Braud
Honoraria - BMS; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Incyte; Nerviano Medical Sciences; Novartis Italy; Roche; Sanofi; Teofarma
Research Funding - Kymab (Inst); Loxo (Inst); Merck Serono (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Jose Luis Perez-Gracia
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Eisai; MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Incyte (Inst); Janssen (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Casilda Llácer Pérez
Honoraria - Roche
Travel, Accommodations, Expenses - Angelini Pharma; Astellas Pharma
 
Sang Joon Shin
No Relationships to Disclose
 
Bruno Fang
No Relationships to Disclose
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Marco Maruzzo
No Relationships to Disclose
 
Sergio Bracarda
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Exelixis/Ipsen; Ipsen; Janssen; Pfizer; Roche
 
Miso Kim
Consulting or Advisory Role - AstraZeneca; Ipsen; MSD; Roche
 
Yannick Kerloeguen
Employment - Roche
 
Jorge Daniel Gallo
Employment - Roche
 
Sophia Maund
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Adam Harris
Employment - Genentech
 
Kuan-Chieh Huang
Employment - Genentech
 
Dhruvitkumar S. Sutaria
Employment - Genentech
 
Howard Gurney
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - Merck Serono
Travel, Accommodations, Expenses - AstraZeneca